VTVT Stock — vTv Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases with the goal of improving patient outcomes. Our lead product candidate, cadisegliatin (TTP399) , is a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated in a Phase 3 clinical trial as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D).

Source: 10-K FY2025 via SEC EDGAR

Share price

$21.03

Market cap

$83.2M

Cash

$77.2M

Enterprise value

$6.0M

Balance sheet

Cash	$77.2M
Debt	$0.0M
Net cash	$77.2M
Enterprise value	$6.0M
Basic shares	3.9M shares
Fully diluted shares	19.3M shares
Fully diluted market cap	$404.9M
Cash per share	$19.59
Quarterly burn	$11.4M
Cash runway	7.6 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

3.9M

Pre-funded warrants

8.5M

Options

1.5M

RSUs

—

Warrants

5.2M

Converts

—

Conv preferred

—

ESPP reserve

—

FDSO

19.3M

Cap table as of 2026-03-10.

Price history

Loading VTVT daily closes…

Loading price history…

Next catalyst

Cadisegliatin 800 mg QD · May 13 - Jun 24 in 6 mo · Phase 3 · Diabetes Mellitus, Type 1

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
May 13 - Jun 24 in 6 mo	Cadisegliatin 800 mg QD	Phase 3	Diabetes Mellitus, Type 1	—
May 13 - Jun 24 in 6 mo	Cadisegliatin 800 mg QD	Phase 2	Type 1 Diabetes (T1D)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

cadisegliatin

Phase 3 · Active Modality: small molecule (oral)

Aliases TTP399

Target glucokinase

Partnerships G42 Healthcare Research Technology Projects LLC (collaboration and license; joint development and commercialization of cadisegliatin in the Middle East, Africa and Central Asia; single-digit royalties); Novo Nordisk (worldwide exclusive license to GKA program; milestones plus mid-single-digit royalties)

Indications

Type 1 diabetes, adjunctive to insulin (Phase 3)
Type 2 diabetes (insulin-using patients) (Phase 2)

Catalysts

— third quarter of 2026
— late 2026

Status note Liver-selective glucokinase activator. FDA granted Breakthrough Therapy designation in 2021 for T1D adjunctive-to-insulin use. Phase 3 CATT1 trial resumed May 2025. Phase 2 trial in insulin-using T2D patients in the Middle East initiated December 2025 with G42. Additional registrational studies for T1D expected to start in 2027.

HPP737

Stage not disclosed · Active Modality: small molecule (oral)

Target PDE4

Partnerships Newsoara Biopharma Co., Ltd. (exclusive global license, Second Amendment January 2026; $20M upfront received February 2026; up to ~$50M development milestones, $65M sales milestones, mid-single-digit royalties)

Indications

Not disclosed (Stage not disclosed)

Status note Development and commercialization handled by Newsoara under expanded global rights (Second Amendment, January 2026; upfront fee received February 2026).

azeliragon

Stage not disclosed · Active Modality: small molecule (oral)

Target RAGE (receptor for advanced glycation end-products)

Partnerships Cantex Pharmaceuticals, Inc. (exclusive worldwide license, June 2021; Cantex responsible for development and commercialization; tiered downstream profit arrangement)

Indications

Not disclosed (Stage not disclosed)

Status note Cantex holds exclusive worldwide rights to develop and commercialize azeliragon, vTv's novel RAGE antagonist.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Cadisegliatin 800 mg QD
Lead indication	Diabetes Mellitus, Type 1
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06334133	Phase 3	Active, not recruiting	Sponsor	vTv Therapeutics	—	Diabetes Mellitus, Type 1	—
NCT07616206	Phase 2	Not yet recruiting	Sponsor	vTv Therapeutics	—	Type 1 Diabetes (T1D)	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for vTv Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	148,314	no change	0.03%	2026-08-14
Aisling Capital	50,000	+50,000	0.40%	2026-08-13

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

VTVT — vTv Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

VTVT — vTv Therapeutics Inc.